Fragrantia Investments

Fragrantia Investments is a private investment holding company primarily associated with entrepreneur Christian Angermayer and his family office, Apeiron Investment Group. The company focuses on strategic investments within the life sciences, biotechnology, and healthcare sectors, with a significant emphasis on mental health treatments and psychedelic medicine. It is most notably recognized as a major shareholder in Atai Life Sciences, a clinical-stage biopharmaceutical company developing innovative therapies for depression, anxiety, and addiction. Fragrantia plays a key role in funding and supporting early-stage ventures that aim to address unmet medical needs through breakthrough scientific research. As a private vehicle, it operates as a strategic financier rather than a direct drug developer.